INSPIRIS中国PMCF研究 (INSPIRIS China)
Edwards Lifesciences INSPIRIS RESILIA 主动脉瓣在中国人群中的上市后临床随访研究
The objective of this post-market trial is to evaluate long term safety and performance of the Edwards Lifesciences INSPIRIS RESILIA aortic valve in Chinese patients in a real-world clinical setting.
研究概览
详细说明
The trial is a multi-center, prospective, single-arm study that will implant up to 250 subjects with the Edwards INSPIRIS RESILIA aortic valve and will continue to follow and assess them after implant for 5 years. In an effort to obtain sufficient long-term data, all subjects will be asked to reconsent to extended follow-up through 10 years.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100037
- Fuwai Hospital, CAMS & PUMC
-
Beijing、Beijing Municipality、中国、100029
- Beijing Anzhen Hospital, Capital Medical University
-
-
Fujian
-
Xiamen、Fujian、中国、361008
- Xiamen Cardiovascular Hospital Xiamen University
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510080
- The First Affiliated Hospital, Sun Yat-sen University
-
Shenzhen、Guangdong、中国、518038
- Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen
-
-
Henan
-
Zhengzhou、Henan、中国、450052
- The First Affiliated Hospital of Zhengzhou University
-
Zhengzhou、Henan、中国、450008
- Henan Provincial Chest Hospital
-
Zhengzhou、Henan、中国、451460
- Fuwai Central China Cardiovascular Hospital
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210012
- Nanjing First Hospital
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710065
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Sichuan
-
Chengdu、Sichuan、中国、610072
- Sichuan Academy of Medical Sciences·Sichuan Provincial People's Hospital
-
-
Yunnan
-
Kunming、Yunnan、中国、650102
- Fuwai Yunnan Cardiovascular Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Subjects requiring an elective replacement of their native or prosthetic aortic valve who have agreed to participate in the study.
描述
Inclusion Criteria:
- Subject is 18 years or older
- Subjects requiring an elective replacement of their native or prosthetic aortic valve as indicated per the IFU
- Subject is scheduled to undergo planned aortic valve replacement with or without concomitant coronary bypass surgery, with or without ascending aorta replacement
- Provide signed informed consent prior to the study participation
Exclusion Criteria:
- Valve implantation is contraindicated per the IFU
- Requires planned multiple valve replacement/ repair
- Has active endocarditis/myocarditis prior to the scheduled aortic replacement surgery
- Estimated Life expectancy< 12 months
- Current or recent participation (within 6 weeks prior to surgery) in another drug or device trial
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
EDWARDS INSPIRIS RESILIA Aortic Valve
Subjects who were treated with the INSPIRIS RESILIA aortic heart valve. |
Surgical replacement of the aortic valve with the INSPIRIS RESILIA Aortic Valve. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Subject's Occurrence Rate of Study Valve Related Death
大体时间:10 Years
|
The primary safety endpoint is the percentage of study valve related death which includes death caused by structural valve deterioration, nonstructural dysfunction, valve thrombosis, embolism, bleeding event, or operated valve endocarditis; death related to reintervention on the operated valve; or sudden, unexplained death. |
10 Years
|
|
Subject's Occurrence Rate of Structural Valve Deterioration
大体时间:10 Years
|
The primary safety endpoint is the percentage of Structural Valve Deterioration which includes dysfunction or deterioration involving the operated valve (exclusive of infection or thrombosis), as determined by re-operation, autopsy, or clinical investigation. |
10 Years
|
|
Subject's Occurrence Rate of Re-operation on the Study Valve
大体时间:10 Years
|
The primary safety endpoint is the reoperation rate on the study valve which is any operation that repairs, alters, or replaces the study valve, which occurs after the completion of the procedure and the transfer out of the procedure room. |
10 Years
|
|
Subject's Occurrence Rate of Major Bleeding
大体时间:10 Years
|
The primary safety endpoint is the rate of major bleeding which is any episode of major internal or external bleeding that causes death, hospitalization, or permanent injury (e.g. Vision loss) or necessitates transfusion of 3 or more units of PRBC, pericardiocentesis, or exploration/reoperation for bleeding. |
10 Years
|
|
Subject's Occurrence Rate of Thromboembolic Events
大体时间:10 Years
|
The primary safety endpoint is the rate of thromboembolic events which is an embolic event that occurs in absence of infection (endocarditis) starting from anesthesia time. Embolism may be manifested by a neurologic event (Stroke or Transient Ischemic Attack) or a non-cerebral embolic event. |
10 Years
|
|
Subject's Occurrence Rate of Stroke
大体时间:10 Years
|
The primary safety endpoint is the rate of strokes which is a prolonged (>72 hours) or permanent neurologic deficit that is usually associated with abnormal results of magnetic resonance imaging or computed tomographic scans. |
10 Years
|
|
Subject's Occurrence Rate of Transient Ischemic Attack
大体时间:10 Years
|
The primary safety endpoint is the rate of transient ischemic attacks which is characterized by fully reversible symptoms of short duration. |
10 Years
|
|
Subject's Occurrence Rate of Non-Cerebral Thromboembolism
大体时间:10 Years
|
The primary safety endpoint is the rate of non-cerebral thromboembolism which is an embolus documented operatively, at autopsy, or clinically that produces signs or symptoms attributable to complete or partial obstruction of a peripheral artery (does not include deep vein thrombosis). |
10 Years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Subject's Average Mean Gradient at 10 Years
大体时间:10 Years
|
Hemodynamic performance - Mean gradients as evaluated by echocardiography |
10 Years
|
|
Subject's Average Peak Gradient at 10 Years
大体时间:10 Years
|
Hemodynamic performance - Peak gradients as evaluated by echocardiography |
10 Years
|
|
Subject's Average Effective Orifice Area at 10 Years
大体时间:10 Years
|
Hemodynamic performance - Effective Orifice Area evaluated by echocardiography |
10 Years
|
|
Subject's Average Effective Orifice Area Index at 10 Years
大体时间:10 Years
|
Hemodynamic performance - Effective Orifice Area Index evaluated by echocardiography |
10 Years
|
|
Amount of Aortic Central Regurgitation in Subjects at 10 Years
大体时间:10 Years
|
Hemodynamic performance - Aortic central regurgitation evaluated by echocardiography |
10 Years
|
|
Amount of Aortic Paravalvular Regurgitation in Subjects at 10 Years
大体时间:10 Years
|
Hemodynamic performance - Aortic paravalvular regurgitation evaluated by echocardiography |
10 Years
|
合作者和调查者
合作者
调查人员
- 首席研究员:Hansong Sun, Professor、Chinese Academy of Medical Sciences, Fuwai Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 2021-09
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data will not be available to other researchers.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.